Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Titel:
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Auteur:
Sartore-Bianchi, Andrea Trusolino, Livio Martino, Cosimo Bencardino, Katia Lonardi, Sara Bergamo, Francesca Zagonel, Vittorina Leone, Francesco Depetris, Ilaria Martinelli, Erika Troiani, Teresa Ciardiello, Fortunato Racca, Patrizia Bertotti, Andrea Siravegna, Giulia Torri, Valter Amatu, Alessio Ghezzi, Silvia Marrapese, Giovanna Palmeri, Laura Valtorta, Emanuele Cassingena, Andrea Lauricella, Calogero Vanzulli, Angelo Regge, Daniele Veronese, Silvio Comoglio, Paolo M Bardelli, Alberto Marsoni, Silvia Siena, Salvatore